83265-53-6

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2-Amino-5-trifluoromethyl-benzoic acid is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to contribute to the development of new drugs and pesticides. Its unique structure allows for the creation of compounds with specific biological activities, enhancing the effectiveness of these products.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Amino-5-trifluoromethyl-benzoic acid is utilized as a building block for the creation of dyes, pigments, and other organic compounds. Its presence in these syntheses can influence the properties of the final products, such as color, stability, and reactivity.
Used in Material and Polymer Production:
2-Amino-5-trifluoromethyl-benzoic acid also finds application in the industrial sector, particularly in the production of polymers and materials. Its incorporation can impart specific characteristics to these materials, such as enhanced stability, improved mechanical properties, or specialized interactions with other molecules, broadening their range of applications.

Upstream product

• 345-32-4 5-(trifluoromethyl)isatin 
• 117324-58-0 methyl 2-Amino-5-trifluoromethylbenzoate 
• 141940-29-6 2-(tert-butoxycarbonylamino)-5-(trifluoromethyl)benzoic acid 
• 1214373-54-2 2-nitro-5-(trifluoromethyl)benzoic acid 
• 454-92-2 3-(trifluoromethyl)benzoic acid 
• 402-59-5 N-(4-trifluoromethylphenyl)-2-oxyiminoacetamide 

Downstream Products

• 220107-65-3 2-Amino-5-(trifluoromethyl)benzyl alcohol 
• 117324-58-0 methyl 2-Amino-5-trifluoromethylbenzoate 
• 16544-67-5 6-(trifluoromethyl)-3Η-quinazolin-4-one 
• 16544-67-5 6-(trifluoromethyl)quinazolin-4-ol 

Relevant academic research and scientific papers

Discovery of Novel Tacrine-Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer's Disease

Based on a multitarget strategy, a series of novel tacrine-pyrimidone hybrids were identified for the potential treatment of Alzheimer's disease (AD). Biological evaluation results demonstrated that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE) and glycogen synthase kinase 3 (GSK-3). The optimal compound 27g possessed excellent dual AChE/GSK-3 inhibition both in terms of potency and equilibrium (AChE: IC50 = 51.1 nM; GSK-3β: IC50 = 89.3 nM) and displayed significant amelioration on cognitive deficits in scopolamine-induced amnesia mice and efficient reduction against phosphorylation of tau protein on Ser-199 and Ser-396 sites in glyceraldehyde (GA)-stimulated differentiated SH-SY5Y cells. Furthermore, compound 27g exhibited eligible pharmacokinetic properties, good kinase selectivity, and moderate neuroprotection against GA-induced reduction in cell viability and neurite damage in SH-SY5Y-derived neurons. The multifunctional profiles of compound 27g suggest that it deserves further investigation as a promising lead for the prospective treatment of AD.

QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES AS TRCP5 MODULATORS FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS

This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.

Novel Heterocyclidene Acetamide Derivative

A compound represented by formula (I′): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group,

Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics

The discovery and initial optimization of a novel anthranilic acid derived class of antibacterial agents has been described in a recent series of papers. This paper describes the discovery of 1-acylindazol-3-ols as a novel bioisostere of an anthranilic acid. The synthesis and structure-activity relationships of the indazol bioisosteres are described herein.

NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE

A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group,

SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS

Compounds of formula (I) wherein R is hydrogen, lower alkyl, (C3-C8)cycloalkyl, hydroxy, halo, lower alkoxy, trifluoromethoxy, trifluoromethyl or cyano; and A is biaryl, optionally substituted β-naphthyl, bicyclic heterocyclic aryl, (C3-C6)cycloalkylmonocyclic carbocyclic aryl, or (C5 or C6)cycloalkane fused-monocyclic carbocyclic aryl; pharmaceutically acceptable salts thereof, and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.

QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS

The present invention relates to quinazoline compounds of formula (I) useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. or a pharmaceutically acceptable derivative thereof, wherein R1, X, R3, x, and ring A are as defined in the present application.

Antimicrobial activity of fluorinated 1,2-benzisothiazol-3(2H)-ones and 2,2'-dithiobis(benzamides)

Fluoro and trifluoromethyl derivatives of 1,2-benzisothiazol-3(2H)-ones and the 2,2'-dithiobis(benzamides) have been prepared and their antifungal and antibacterial activity evaluated. Several compounds were found highly active against fungi and Gram-positive microorganisms and a few derivatives displayed some activity against Gram-negative strains. Structure-activity relationships are proposed.

Anthranilic acid derivatives

Agents for lowering glucose levels in blood having the formula: STR1 wherein Ro is bromo, chloro, fluoro, nitro or trifluoromethyl, R is hydrogen, C1-6 alkyl or C2-18 alkanoyl, and R1 is hydrogen or C1-12 alkyl, and the non-toxic, pharmaceutically acceptable salts thereof.